本研究的不足之处在于仅将两种治疗方案的临床疗效进行对比分析，鉴于目前繁

The disadvantage of this study is that only the clinical efficacy of the two treatment options are compared and analyzed. In view of the current cumbersome grading of chemotherapeutic drug adverse reactions and PD-1 monoclonal antibody drug adverse reaction grading, and there is no unified grading plan for related adverse reactions For the time being, the side effects and adverse reactions of the two groups of patients have not been compared and analyzed to further confirm the feasibility of the treatment plan. We are also actively accumulating cases and related experience to lay the foundation for further research. <br>references:

The shortcoming of this study is that only the clinical efficacy of the two treatment options is compared and analyzed, in view of the current cumbersome classification of adverse reactions of chemotherapy drugs and PD-1 single anti-drug adverse reaction classification, as well as the absence of a unified classification of adverse reactions, the drug side effects and adverse reactions of the two groups of patients have not been compared and analyzed to further confirm the feasibility of the treatment plan. We are also actively accumulating cases and related experiences to lay the groundwork for further research.<br>References:

The disadvantage of this study is that only the clinical efficacy of the two treatment schemes were compared and analyzed. In view of the cumbersome classification of adverse reactions of chemotherapy drugs and PD-1 monoclonal antibody, as well as the lack of a unified classification scheme of related adverse reactions, there is no comparative analysis on the side effects and adverse reactions of the two groups of patients, so as to further confirm the treatment The feasibility of the case. We are also actively accumulating cases and relevant experience to lay a foundation for further research.<br>reference:<br>